National Institute of Cardiology Ignacio Chavez, Mexico City, Mexico.
Autonomous University of Chihuahua, Chihuahua, Mexico.
Methodist Debakey Cardiovasc J. 2024 Aug 20;20(4):109-112. doi: 10.14797/mdcvj.1430. eCollection 2024.
Chemotherapy has markedly improved cancer outcomes, yet cancer therapy-related cardiac dysfunction (CTRCD) poses a significant challenge, affecting around 10% of patients. CTRCD can be asymptomatic or present with heart failure symptoms. Multimodality imaging, particularly echocardiography, remains pivotal for monitoring cardiac function. Potential biomarkers for CTRCD assessment include troponin and B-type natriuretic peptide. Pharmacological interventions, such as dexrazoxane, angiotensin-converting enzyme inhibitors, and statins, play a crucial role in primary prevention and mitigating cardiotoxicity alongside cardiac rehabilitation programs. Thus, a comprehensive approach is essential for optimal cardiac recovery and improved patient outcomes.
化疗显著改善了癌症患者的预后，但癌症治疗相关的心脏功能障碍（CTRCD）仍是一个重大挑战，大约 10%的癌症患者会发生 CTRCD。CTRCD 可无症状，也可表现为心力衰竭症状。多模态影像学，特别是超声心动图，仍是监测心脏功能的关键。用于评估 CTRCD 的潜在生物标志物包括肌钙蛋白和 B 型利钠肽。药物干预，如右雷佐生、血管紧张素转换酶抑制剂和他汀类药物，在初级预防和减轻心脏毒性以及心脏康复计划中发挥着至关重要的作用。因此，综合治疗方法对于实现心脏的最佳恢复和改善患者预后至关重要。
